Skip to content

Does Personality Predict Patient Adherence, Health Behaviors, and Weight Loss Outcomes During the Latino Crossover Semaglutide Study (LCSS)? (Story-LCSS Project)

Does Personality Predict Patient Adherence, Health Behaviors, and Weight Loss Outcomes During the Latino Crossover Semaglutide Study (LCSS)? (Story-LCSS Project)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05622045
Acronym
StoryLCSS
Enrollment
59
Registered
2022-11-18
Start date
2023-02-01
Completion date
2027-05-01
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Body Weight Changes, Obesity

Keywords

artificial intelligence, obesity, weight loss

Brief summary

The goal of this observational study is to learn about the personality attributes and values of people living with obesity that are part of the Latino community, and how these personality attributes and values can help to predict success during a weight loss program. The main questions it aims to answer are: * What are the personality attributes and values of people living with obesity that sign up to the LCSS-Latino Crossover Semaglutide Study trial? * Can behavioral artificial intelligence (a computer formula) predict which patients will complete the LCSS-Latino Crossover Semaglutide Study trial? * How do behavioral artificial Intelligence predictions (a computer formula) compare to clinician predictions of patient success? * Can behavioral artificial intelligence (a computer formula) predict patient weight loss, calorie consumption and physical activity levels during the LCSS-Latino Crossover Semaglutide Study trial? Participants will be recorded in English and Spanish while responding to a question regarding participation in a weight loss study.

Interventions

BEHAVIORALVoice data

Recorded response to a question about their participation in a weight loss study.

Sponsors

Loma Linda University
Lead SponsorOTHER
Scaled Insights
CollaboratorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 74 Years

Inclusion criteria

* Participation in the LCSS-Latino Crossover Semaglutide Study

Exclusion criteria

* Not a participant of the LCSS-Latino Crossover Semaglutide Study at the point of data collection

Design outcomes

Primary

MeasureTime frameDescription
Predicted patient weight change successThe voice data measurement will take place at baseline and take about 10-15 minutes for collection to take place.Predicted patient weight change as determined by Scaled Insights Behavioural Artificial Intelligence based on subject voice data. Weight loss exceeding 5-10 pounds over 6 months will be considered to be successful. Predicted weight change will be compared to the weight change measured in a separate clinical trial \[Latino Crossover Semaglutide Study (LCSS) NCT05087342\]. Similar weight change values between the predicted and measured outcomes will indicate that the Scaled Insights Behavioural Artificial Intelligence is good predictor.
Clinician predictionsThe clinician judgement will be measured during the second month of the subject's weight loss study.Clinician (physician) judgement of patient weight loss success during a weight loss study.
Predicated patient calorie intakeThe voice data measurement will take place during the subject's initial clinic visit and take about 10-15 minutes for collection to take place.Predicted patient calorie intake as determined by Scaled Insights Behavioural Artificial Intelligence based on subject voice data. Predicted calorie intake will be compared to the calorie intake measured in a separate clinical trial \[Latino Crossover Semaglutide Study (LCSS) NCT05087342\]. Similar calorie values between the predicted and measured outcomes will indicate that the Scaled Insights Behavioural Artificial Intelligence is good predictor.
Predicated patient physical activity levelThe voice data measurement will take at baseline and take about 10-15 minutes for collection to take place.Predicted patient physical activity level as determined by Scaled Insights Behavioural Artificial Intelligence based on subject voice data. Predicted physical activity will be compared to the physical activity measured in a separate clinical trial \[Latino Crossover Semaglutide Study (LCSS) NCT05087342\]. Similar physical activity level values between the predicted and measured outcomes will indicate that the Scaled Insights Behavioural Artificial Intelligence is good predictor.

Secondary

MeasureTime frameDescription
Personality attributes and valuesThe voice data measurement will take place at baseline and take about 10-15 minutes for collection to take place.Extrapolated personality attributes and values as determined by Scaled Insights Behavioural Artificial Intelligence based on subject voice data. These are qualitative non-numerical descriptors.
Predicted patient attrition rateThe voice data measurement will take place at baseline and take about 10-15 minutes for collection to take place.Predicted patient attrition rate from the weight loss study as determined by Scaled Insights Behavioural Artificial Intelligence based on subject voice data. Predicted patient attrition rate will be compared to the attrition rate occurring during the weight loss study. Similar attrition rates between the predicted and actual rates will indicate that the Scaled Insights Behavioural Artificial Intelligence is good predictor.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORCeline Heskey, DrPH

Loma Linda University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 9, 2026